Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1521498 in Obese Subjects with Over-Eating Behaviours
NCT01195792Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK-1521498 in obesity (3 arms), sponsored by GSK. Primary endpoint: Clinically and statistically significant weight loss at 35 days. Started Sep 2010; status: completed.
02
Drugs
GSK-1521498
03
Conditions
obesity
Beyond the preview
Go deeper on NCT01195792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01195792.